Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

patients with metastatic osteosarcoma treated in earlier Phase 2 studies. The biological effects and safety of L-MTP-PE are further supported by data from 7 other Phase 1 and 2 clinical studies performed under IND, in which an additional 197 patients received at least one dose of L-MTP-PE.

L-MTP-PE was granted orphan drug status in the United States in 2001. The NDA for L-MTP-PE was submitted to the U.S. Food and Drug Administration (FDA) in October 2006 and was accepted for review in December 2006.

The FDA's Oncologic Drugs Advisory Committee, or ODAC, met in May 2007 and voted 12 to 2 that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy. In July 2007, following a meeting with the FDA, the Company announced plans to collect, analyze and submit additional data for L-MTP-PE to the FDA, in an amendment to the NDA, by the first quarter of 2008. In August 2007 the FDA, considering ODAC's recommendation, issued a not approvable letter to the Company after completing the review of the NDA for L-MTP-PE. In this letter, the FDA requested data from additional clinical trials to demonstrate the benefit of L-MTP-PE, as well as information or clarification with respect to other sections of the NDA.

IDM Pharma also is seeking marketing approval from the European Medicines Agency (EMEA) for the use of L-MTP-PE, or MEPACT as it is known in Europe. L-MTP-PE was granted orphan drug status in Europe in 2004. The Marketing Authorization Application (MAA) for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006. The EMEA application is currently under review and the Company continues to work closely with the regulatory body by providing as much additional data as possible and responding to ongoing inquiries from reviewers. The Company expects that the Committee for Human Medicina
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Academy, senescent is he who "begins to age". But ... is senescence not a synonym of ageing, it is ... is such a badly named physiological process that those ... another name. That is the case of Manuel Serrano, ... of the world,s leading experts on senescence, who has ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 The ... & Services [Physical Security, Life Safety, Facility Management], ... Worldwide Forecast & Analysis (2014 - 2019)” defines ... with an in-depth analysis and forecasting of revenues. ... market, various restraints and opportunities impacting it, along ...
(Date:7/14/2014)... into an agreement with one of the world,s ... candidates for the detection and treatment of cancer. ... antibody discovery and Roche,s expertise in developing monoclonal ... of improved treatment for cancer, a leading cause ... use of BTI,s discovery of a new mechanism ...
(Date:7/14/2014)... Secure Decisions, a leading provider of assessment ... Software Assurance Marketplace (SWAMP) to build a powerful and ... everyday life. , The SWAMP, implemented by a group ... Institute for Research, is funded by the Department of ... by building a free facility with a diverse repository ...
(Date:7/14/2014)... with improving vision, cataract surgery may slow mental decline ... dementia, a new study suggests. Better eyesight also ... "These preliminary results indicate that improved vision can have ... their loved ones, both visual and non-visual," said Dr. ... Hospitals Case Medical Center, in Ohio. Cataract surgery ...
Breaking Medicine News(10 mins):Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2
... , Preliminary research on Fusarium , a group ... animals, shows how these microbes travel through the air. ... preliminary research, there will be a better understanding about ... biologists are steering their efforts towards a new aerobiological ...
... malaria vaccine that uses the entire malaria parasite has proven ... in a clinical trial, according to a new study co-authored ... Center for Vaccine Development. The vaccine is unique in that ... vaccines consist of just one or at most a few ...
... Institute in Boston and the Scripps Research Institute in ... powerful anti-diabetic effects, yet apparently free at least ... current diabetes medications. The researchers say that their ... 2 diabetes, which affects more than 25 million children ...
... HealthDay Reporter , FRIDAY, Sept. 9 (HealthDay News) -- ... were to meet Friday to discuss problems linked to ... Boniva and Reclast. These drugs, known as ... osteoporosis. But researchers have linked long-term use with a ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- Many ... infant. But sometimes that concern develops into an obsession over ... that condition postpartum obsessive compulsive disorder. It can drive women ... true, such as endlessly washing the infant to stave off ...
... at the University of Ottawa Heart Institute (UOHI) have ... and exports cholesterol from cells. A team ... Biology Laboratory, UOHI, has shown that autophagy, a pathway ... accumulated in artery walls. This process facilitates the removal ...
Cached Medicine News:Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 2Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 3Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 4Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 5Health News:New twist in diabetes drugs could reduce life-threatening side effects 2Health News:New twist in diabetes drugs could reduce life-threatening side effects 3Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:When Protecting Baby Becomes an Obsession 2Health News:When Protecting Baby Becomes an Obsession 3Health News:Researchers find process that clears cholesterol and could reverse major cause of heart attack 2
(Date:7/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Harmony Foundation, Colorado,s ... Estes Park , will break ground for a new ... am on Harmony,s campus. The public is welcome to attend ... of Harmony,s $10 million Support & Renew Capital Campaign ... and complex addiction rates in Colorado . ...
(Date:7/14/2014)...  More than any other generation, Millennials born in the ... but their eyes don,t. These mobile devices demand a type ... eye has not evolved to cope with them. The gap ... comfortably often results in tired eyes, focusing problems, headaches and ... Now ZEISS has invented a new type of lens for ...
(Date:7/14/2014)...  GenSpera, Inc. (OTCQB: GNSZ), a leader in ... announces that Kareg Corporation,s Director of Research, ... research report on  the company. ... Kareg Corporation, Initiating Coverage with a Speculative Buy ... http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ is attractive ...
Breaking Medicine Technology:Harmony Foundation Breaking Ground on Addiction Health Center 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: